Egle Therapeutics Appoints John Celebi as New CEO
PARIS, Jan. 07, 2026 (GLOBE NEWSWIRE) — Egle Therapeutics SAS, a pioneering clinical-stage biotechnology company specializing in precision medicines that modulate regulatory T cells (Tregs), has announced the appointment of John Celebi, M.B.A., as the new Chief Executive Officer. With over 30 years of experience in the biotechnology sector, Celebi's leadership is expected to enhance Egle's focus on developing innovative therapies for autoimmune diseases and cancer, aligning with the company's strategic goals in this fast-evolving market.
Strategic Appointment Amid Clinical Development Focus
John Celebi's appointment comes at a crucial time as Egle Therapeutics intensifies its clinical development efforts centered on autoimmune diseases. Recent validation of the IL-2 mechanism presents significant opportunities for differentiated therapeutic solutions, particularly in major indications. Egle's lead programs include novel IL-2 receptor alpha-biased muteins crafted for best-in-class selectivity to regulatory T cells. This innovation offers promising potential for deeper efficacy, improved safety profiles, and sustained immune rebalancing without the risk of Treg exhaustion.
Highlights of John Celebi's Career
Prior to this role, John Celebi served as CEO of Sensei Bio (NASDAQ: SNSE), where he successfully led the company through critical growth phases. His tenure included:
- Closing a successful $152 million initial public offering.
- Raising over $220 million in total equity capital.
- Establishing a robust clinical-stage pipeline.
Before working with Sensei Bio, Celebi made significant contributions at ArQule, negotiating over $1.5 billion in strategic partnerships with leading pharmaceutical companies such as Roche and Daiichi-Sankyo. Moreover, he held the role of Chief Business Officer at Igenica Biotherapeutics, where he successfully aligned the company with AstraZeneca through strategic collaborations.
CEO Vision and Future Initiatives
Mr. Celebi expressed his enthusiasm for his new role, stating, “I am honored to expand my role at Egle as Chief Executive Officer and build on the strong foundation already in place.” He emphasizes the compelling potential of the company’s differentiated IL-2-based Treg modulators to offer meaningful therapies for patients. “With our healthy volunteer single ascending dose data anticipated in the first half of 2026,” he added, “I look forward to leveraging my experience in drug development and strategic partnerships to move Egle's innovative science forward."
About Egle Therapeutics
Egle Therapeutics is a clinical-stage biotechnology firm dedicated to developing precision medicines that modulate Tregs to rebalance immune functions in patients affected by autoimmune diseases and cancer. The company's proprietary technology platform focuses on engineering highly selective IL-2 variant immuno-conjugates aimed at overcoming previous efficacy and safety challenges in Treg-focused therapies. Egle's autoimmunity portfolio includes:
- EGL-003: An IL-2 agonist Treg engager targeting conditions like atopic dermatitis.
- EGL-001: An anti-CTLA-4-IL-2m fusion that recently commenced first-in-human dosing.
- EGL-002: An anti-CCR8 x anti-CD25 bispecific agent.
For more detailed information, visit the official website at www.egle-tx.com and follow Egle on LinkedIn.
Contact Information
For media inquiries, please contact:
- Email: contact@egle-tx.com
- Phone: +33 (0)1 86 64 08 57
- Investor Relations: investor.relations@egle-tx.com